HFA Premium Access

Novel drugs - how do they work?

Event: HEART FAILURE 2016
Topic: Miscellaneous
Session type: Abstract Sessions
Date: 21 May 2016
Time: 08:30 - 10:00

Congress Session

6 presentations in this session

Novel drugs in heart failure: what's on the horizon?

Speaker: Professor C. Maack (Wuerzburg, DE)
Thumbnail

Effects of serelaxin on a systolic cardiac dysfunction induced by isoproterenol in mice with increased cardiac aldosterone

Speaker: Doctor G. Billebeau (Paris, FR)
Thumbnail

Why treatment with natriuretic peptide analogs failed to fulfill our expectations? - receptor expression and function in a failing heart.

Speaker: Doctor K. Kodziszewska (Warsaw, PL)
Thumbnail

ORM-3819 promotes cardiac contractility on a dual mechanism of action: troponin-C dependent calcium sensitization is supported by selective PDE III inhibition

Speaker: Doctor L. Nagy (Debrecen, HU)
Thumbnail

Vepoloxamer (purified poloxamer-188) improves LV function, limits cardiomyocyte calcium overload and restores integrity of calciu cycling proteins in myocardium of dogs with advanced heart failure

Speaker: Professor H. Sabbah (Detroit, US)
Thumbnail

Targeting HDACs in heart failure.

Thumbnail

5 speakers from this session

Professor Christoph Maack

University Clinic Wuerzburg, Wuerzburg (Germany)
25 presentations
0 follower

Doctor Gilles Billebeau

Hospital Lariboisiere, Paris (France)
0 follower

Doctor Katarzyna Kodziszewska

National Institute of Cardiology, Warsaw (Poland)
0 follower

Doctor Laszlo Nagy

University of Debrecen, Debrecen (Hungary)
0 follower

Professor Hani Sabbah

Henry Ford Hospital, Detroit (United States of America)
2 presentations
0 follower

This platform is supported by

logo Novo Nordisk